A strategic fund of a large biopharmaceutical group focuses its investment strategy on oncology and infectious diseases. The fund has $150M under management and invests in the range of $1M – $10M per company. The Fund typically seeks to participate in Series A/B rounds, and is currently seeking 1-3 new equity investment opportunities a year. The fund also supports the in-licensing activities of the parent company in the EU and U.S.

The fund is mainly seeking digital health and healthcare IT investment opportunities at pre-commercial or commercial stage that will either improve drug development (e.g. patient recruitment, best responders, combination therapy) or that will impact the patient journey (e.g. patient monitoring, digital therapeutics, clinical decision support systems). In addition the firm considers therapeutic and diagnostic proposals that relate to oncology and infectious diseases. The fund is also seeking oncology and infectious disease therapeutics to in-license. The Fund is agnostic in terms of stage of development.

The fund is very active and supportive with their portfolio companies. The Fund typically seeks a board seat, and at times, also an observer seat. The Fund is looking for management teams experienced in the domain of interest and with entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund backed by a family-office makes seed and early-stage equity investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million of total exposure in any single opportunity. The firm is open to opportunities worldwide but has a preference for domestic investment; the fund currently has portfolio companies in North America, Europe and Oceania.

The first area of focus is Alzheimer’s Disease, where therapeutics (primary), diagnostics (secondary) and other solutions (tertiary) are all valid for consideration. The second area of investment is in technologies that enhance, accelerate, or reduce the cost of clinical trials and basic research, on the broadest scale, beyond Alzheimer’s Disease. This may include hardware and software tools, data analytics or aggregators, or novel approaches to current standards and protocols.

The firm seeks to make early-stage investments, but will also consider later-stage opportunities. The firm’s prior investments include drug discovery for the treatment of Alzheimer’s Disease, a diagnostic to track and recruit patients in early cognitive decline, a tablet-enabled benchtop microscope, an automated imaging tool for micro-dissection of tissue samples, and a platform looking to reinvent the model for pre-human drug testing and development. The fund also has a global partnership to develop intellectual property into potential compound candidates to treat Alzheimer’s Disease.

The firm strongly prefers to invest in privately held companies and will only back top scientists with defendable research, pursuing breakthrough approaches rather than traditional. In their Alzheimer’s portfolio, the fund looks to identify early-stage therapies that have received, and exhausted, non-dilutive sources of funding, such as grants from leading organizations; these companies will ideally be on the radar of large pharma counterparts but looking to obtain additional funds to collect the data required to form pharmaceutical partnerships. In the medical technology sector, the firm prefers to invest in companies developing platform technologies that can demonstrate and defend a clear value proposition addressing the ability to make clinical trials more efficient.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global biotech headquartered in Europe with multiple R&D facilities across the USA and Western Europe has several marketed products in oncology, rare diseases, and neurosciences and has global commercial and development capabilities. The Company is actively seeking to expand its pipeline by working with early stage biotechs and academic groups. The Company is open to a variety of deal structures and seeks to construct deals that maximize the potential of the therapeutic program by leveraging the capabilities of all partners involved while meeting the needs of the entrepreneur/startup. The Company is also an anchor investor in a newly launched venture fund that will have an associated accelerator which will start / fund project focused companies to work in close partnership with their R&D team. This fund will add additional flexibility in the Company’s ability to work with the early stage biotech and academic communities.

The Company is focused on enhancing its pipeline with oncology, rare disease, and select neuroscience drug assets. The Company is interested in highly differentiated late stage pre-clinical and clinical stage therapeutic candidates with strong scientific rationale targeting indications with significant unmet medical need.

The Company has no strict requirements for companies or management teams and looks to work creatively and collaboratively on partnerships with early-stage companies. The Company is open to opportunities/companies on a global basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in the Bay Area and Western Europe manages over $230m investing in Life Sciences companies with a stage agnostic strategy. The initial investment size ranges from $0.5 million for seed stage companies to $5 million for later stages ventures, and reserves significant capital for follow on investments. The fund invests in Europe, US and Israel.

The firm is currently looking for new investment opportunities in therapeutics, medical devices, diagnostics and digital health with a focus on cardiovascular, oncology and neurology although they are opportunistic in other areas.

The firm seeks to invest in both private and public companies based in Europe, US and Israel.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new venture capital firm with headquarters in Europe seeks to make 2-4 equity investments in the range from $1-5M (EUR) per year. The firm is actively seeking new investments globally, with a focus in USA and Europe.

The firm invests in technologies that can treat age-related disease and damages associated with aging, such as altered protein homeostasis, cellular senescence, stem cell exhaustion, etc. The firm will consider companies working in therapeutics, diagnostics, nutritional products and advanced therapy medicinal products (gene therapy, cell therapy, tissue engineering) as long as they are relevant to the firm’s mission in targeting the basic mechanisms contributing to age-related disease. However, medical devices are currently not an area of focus. In therapeutics, the firm looks mostly at pre-clinical technologies with a validated proof-of-concept. The firm will consider companies in their later stages but prefers working with early-stage companies to provide company building and strategic support.

The firm can work with all types of management teams. The firm places higher importance in the actual science or technology in development as well as solid IP position. The firm seeks to work closely with their portfolio companies and can assist with building and structuring a full management team. As the firm generally comes in as the first institutional investor, they prefer to lead rounds and take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences investment firm with a global diversified strategy ranging from seed stage to public companies, is actively involved in innovation, restructuring opportunities, and growth investing. The firm’s investment team brings a wealth of experience across all areas of the life sciences industry. Nearly all of the firm’s partners have been with the firm for 12 years or more, and they are supported by over 20 investment professionals, distinguished advisers, and scientific advisory board members. The firm has no set number of allocations that it plans to make but is actively reviewing new opportunities from around the globe. The firm has a history of strategic relationships with other venture capital firms or funds targeting specific sectors or geographies within the life sciences. These working relationships help give them a global footprint and vastly expand the firm’s deal flow.

The firm’s general life sciences funds represent approximately $1.3 billion in capital commitments. These funds target a diverse group of life sciences companies, across all stages of development. Bay City Capital funds have invested in a total of 100 portfolio companies covering a broad range of life science sectors, including biopharmaceuticals, drug discovery and research tools, medical devices, diagnostics, digital health, nutrition, and agribusiness.

The firm seeks to invest its capital in life sciences companies where their operational, financial, and scientific expertise can assist management in building companies. This investment approach has remained largely consistent since 1997, delivering attractive returns to their investors. Effective management is critical to the success of their portfolio companies. The firm assists their portfolio companies in recruiting and retaining key management and advisors, identifying product opportunities, establishing and negotiating strategic partnerships, and providing assistance with product development and execution. The firm develops close working relationships with their management teams to establish themselves as true partners in business building.

The firm strongly prefers board representation, and have received a board seat with 90% of their portfolio companies (based on invested capital). The firm believes this commitment of intellectual capital increases the likelihood of positive outcomes for their investments, and has established them as a preferred partner in the industry.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences Venture Capital firm based in Toronto with other offices throughout USA and Canada manages over $350M and is currently investing from a recently closed new fund. The firm typically makes initial investments ranging from $2-6 million of equity and looks to invest $8-12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months.

The firm invests primarily in therapeutics and medical devices, with selective investments in diagnostic imaging and digital health. The firm generally looks for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.